Please enable JavaScript to continue using this application.

Compare $COAG vs $RARE | Chartloom

Compare

$COAG vs $RARE

Hemab Therapeutics Holdings Inc · Ultragenyx Pharmaceutical Inc

COAG

Hemab Therapeutics Holdings Inc

RARE

Ultragenyx Pharmaceutical Inc

Compare $COAG vs $RARE

Comparing Hemab Therapeutics Holdings Inc and Ultragenyx Pharmaceutical Inc

COAGHemab Therapeutics Holdings Inc

RAREUltragenyx Pharmaceutical Inc

COAGHemab Therapeutics Holdings Inc

Market cap

$1.48B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-7.0%

52W performance

-7.0%

FCF yield

0.0%

RAREUltragenyx Pharmaceutical Inc

Market cap

$1.52B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.74x

Rev growth (TTM)

17.5%

YTD performance

-34.4%

52W performance

-49.8%

FCF yield

-32.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

COAG

RARE

Detailed metrics comparison

COAG

Hemab Therapeutics Holdings Inc

RARE

Ultragenyx Pharmaceutical Inc

Market Cap

COAG$1.48B

RARE$1.52B

Enterprise Value

COAG$1.24B

RARE$2.54B

Price

COAG$31.62

RARE$15.48

P/E Ratio

COAGN/A

RAREN/A

P/S Ratio

COAG0.00x

RARE2.13x

EV/Sales

COAG0.00x

RARE3.54x

EV/EBITDA

COAG0.00x

RARE0.00x

P/B Ratio

COAG3.20x

RARE163.83x

P/FCF Ratio

COAGN/A

RAREN/A

EV/FCF

COAG0.00x

RARE-5.14x

PEG Ratio

COAGN/A

RAREN/A

Forward P/E (NTM)

COAGN/A

RAREN/A

Forward P/S (NTM)

COAGN/A

RARE1.74x

Revenue (TTM)

COAG$0

RARE$717M

Revenue Growth (YoY)

COAGN/A

RARE17.5%

Forward Rev Growth

COAG1014.0%

RARE27.7%

Gross Margin (TTM)

COAG0.0%

RARE83.1%

Operating Margin (TTM)

COAG0.0%

RARE0.0%

EBITDA Margin (TTM)

COAG0.0%

RARE-69.0%

Net Margin (TTM)

COAG0.0%

RARE-81.7%

FCF Margin (TTM)

COAGN/A

RARE-68.9%

Net Income (TTM)

COAG$-47M

RARE$-586M

FCF (TTM)

COAG$0

RARE$-494M

EPS (TTM)

COAG-$1.00

RARE-$5.75

ROE (TTM)

COAG0.0%

RARE-41417.0%

ROA (TTM)

COAG0.0%

RARE-4437.0%

ROIC (TTM)

COAG0.0%

RARE-5861.0%

Cash

COAG$237M

RARE$125M

Debt

COAG$0

RARE$1.14B

Net Cash/Debt

COAG$237M

RARE$-1.02B

Current Ratio (TTM)

COAG35.85x

RARE1.73x

Quick Ratio (TTM)

COAG35.48x

RARE1.43x

Debt/Equity (TTM)

COAG0.00x

RARE90.54x

Debt/Assets (TTM)

COAG0.0%

RARE0.0%

Interest Coverage (TTM)

COAGN/A

RAREN/A

Net Debt/EBITDA (TTM)

COAG0.00x

RARE0.00x

Beta

COAG-0.87

RARE0.35

52W Performance

COAG-7.0%

RARE-49.8%

YTD Performance

COAG-7.0%

RARE-34.4%

% from 52W High

COAG-42.9%

RARE-61.2%

% from 52W Low

COAG37.5%

RARE21.6%

Asset Turnover (TTM)

COAG0.00x

RARE0.54x

FCF Yield (TTM)

COAG0.0%

RARE-32.4%

Earnings Yield (TTM)

COAG-3.2%

RARE-38.4%

Dividend Yield (TTM)

COAGN/A

RAREN/A

Rule of 40

COAG0.0

RARE-51.4

EV/GP/RG

COAGN/A

RARE0.17

Ticker research

View COAG research View RARE research

Metric	COAG Hemab Therapeutics Holdings Inc	RARE Ultragenyx Pharmaceutical Inc
Market & Valuation
Market Cap	$1.48B	$1.52B
Enterprise Value	$1.24B	$2.54B
Price	$31.62	$15.48
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	2.13x
EV/Sales	0.00x	3.54x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.20x	163.83x
P/FCF Ratio	N/A	N/A
EV/FCF	0.00x	-5.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	1.74x
Revenue & Growth
Revenue (TTM)	$0	$717M
Revenue Growth (YoY)	N/A	17.5%
Forward Rev Growth	1014.0%	27.7%
Profitability
Gross Margin (TTM)	0.0%	83.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-69.0%
Net Margin (TTM)	0.0%	-81.7%
FCF Margin (TTM)	N/A	-68.9%
Net Income (TTM)	$-47M	$-586M
FCF (TTM)	$0	$-494M
EPS (TTM)	-$1.00	-$5.75
ROE (TTM)	0.0%	-41417.0%
ROA (TTM)	0.0%	-4437.0%
ROIC (TTM)	0.0%	-5861.0%
Financial Health
Cash	$237M	$125M
Debt	$0	$1.14B
Net Cash/Debt	$237M	$-1.02B
Current Ratio (TTM)	35.85x	1.73x
Quick Ratio (TTM)	35.48x	1.43x
Debt/Equity (TTM)	0.00x	90.54x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.87	0.35
52W Performance	-7.0%	-49.8%
YTD Performance	-7.0%	-34.4%
% from 52W High	-42.9%	-61.2%
% from 52W Low	37.5%	21.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.54x
FCF Yield (TTM)	0.0%	-32.4%
Earnings Yield (TTM)	-3.2%	-38.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-51.4
EV/GP/RG	N/A	0.17
Ticker research	View COAG research	View RARE research

Valuation

P/S Ratio

COAG

0.00x

RARE

2.13x

EV/FCF

RARE

-5.14x

COAG

0.00x

Growth & revenue

Revenue Growth TTM

RARE

17.5%

Forward Revenue Growth

COAG

1014.0%

RARE

27.7%

Profitability & performance

Gross Margin

RARE

83.1%

COAG

0.0%

ROE

COAG

0.0%

RARE

-41417.0%

FCF Yield %

COAG

0.0%

RARE

-32.4%

52-Week Performance

COAG

-7.0%

RARE

-49.8%

Detailed metrics comparison

COAG

Hemab Therapeutics Holdings Inc

RARE

Ultragenyx Pharmaceutical Inc

Market Cap

COAG$1.48B

RARE$1.52B

Enterprise Value

COAG$1.24B

RARE$2.54B

Price

COAG$31.62

RARE$15.48

P/E Ratio

COAGN/A

RAREN/A

P/S Ratio

COAG0.00x

RARE2.13x

EV/Sales

COAG0.00x

RARE3.54x

EV/EBITDA

COAG0.00x

RARE0.00x

P/B Ratio

COAG3.20x

RARE163.83x

P/FCF Ratio

COAGN/A

RAREN/A

EV/FCF

COAG0.00x

RARE-5.14x

PEG Ratio

COAGN/A

RAREN/A

Forward P/E (NTM)

COAGN/A

RAREN/A

Forward P/S (NTM)

COAGN/A

RARE1.74x

Revenue (TTM)

COAG$0

RARE$717M

Revenue Growth (YoY)

COAGN/A

RARE17.5%

Forward Rev Growth

COAG1014.0%

RARE27.7%

Gross Margin (TTM)

COAG0.0%

RARE83.1%

Operating Margin (TTM)

COAG0.0%

RARE0.0%

EBITDA Margin (TTM)

COAG0.0%

RARE-69.0%

Net Margin (TTM)

COAG0.0%

RARE-81.7%

FCF Margin (TTM)

COAGN/A

RARE-68.9%

Net Income (TTM)

COAG$-47M

RARE$-586M

FCF (TTM)

COAG$0

RARE$-494M

EPS (TTM)

COAG-$1.00

RARE-$5.75

ROE (TTM)

COAG0.0%

RARE-41417.0%

ROA (TTM)

COAG0.0%

RARE-4437.0%

ROIC (TTM)

COAG0.0%

RARE-5861.0%

Cash

COAG$237M

RARE$125M

Debt

COAG$0

RARE$1.14B

Net Cash/Debt

COAG$237M

RARE$-1.02B

Current Ratio (TTM)

COAG35.85x

RARE1.73x

Quick Ratio (TTM)

COAG35.48x

RARE1.43x

Debt/Equity (TTM)

COAG0.00x

RARE90.54x

Debt/Assets (TTM)

COAG0.0%

RARE0.0%

Interest Coverage (TTM)

COAGN/A

RAREN/A

Net Debt/EBITDA (TTM)

COAG0.00x

RARE0.00x

Beta

COAG-0.87

RARE0.35

52W Performance

COAG-7.0%

RARE-49.8%

YTD Performance

COAG-7.0%

RARE-34.4%

% from 52W High

COAG-42.9%

RARE-61.2%

% from 52W Low

COAG37.5%

RARE21.6%

Asset Turnover (TTM)

COAG0.00x

RARE0.54x

FCF Yield (TTM)

COAG0.0%

RARE-32.4%

Earnings Yield (TTM)

COAG-3.2%

RARE-38.4%

Dividend Yield (TTM)

COAGN/A

RAREN/A

Rule of 40

COAG0.0

RARE-51.4

EV/GP/RG

COAGN/A

RARE0.17

Ticker research

View COAG research View RARE research

Metric	COAG Hemab Therapeutics Holdings Inc	RARE Ultragenyx Pharmaceutical Inc
Market & Valuation
Market Cap	$1.48B	$1.52B
Enterprise Value	$1.24B	$2.54B
Price	$31.62	$15.48
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	2.13x
EV/Sales	0.00x	3.54x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.20x	163.83x
P/FCF Ratio	N/A	N/A
EV/FCF	0.00x	-5.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	1.74x
Revenue & Growth
Revenue (TTM)	$0	$717M
Revenue Growth (YoY)	N/A	17.5%
Forward Rev Growth	1014.0%	27.7%
Profitability
Gross Margin (TTM)	0.0%	83.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-69.0%
Net Margin (TTM)	0.0%	-81.7%
FCF Margin (TTM)	N/A	-68.9%
Net Income (TTM)	$-47M	$-586M
FCF (TTM)	$0	$-494M
EPS (TTM)	-$1.00	-$5.75
ROE (TTM)	0.0%	-41417.0%
ROA (TTM)	0.0%	-4437.0%
ROIC (TTM)	0.0%	-5861.0%
Financial Health
Cash	$237M	$125M
Debt	$0	$1.14B
Net Cash/Debt	$237M	$-1.02B
Current Ratio (TTM)	35.85x	1.73x
Quick Ratio (TTM)	35.48x	1.43x
Debt/Equity (TTM)	0.00x	90.54x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.87	0.35
52W Performance	-7.0%	-49.8%
YTD Performance	-7.0%	-34.4%
% from 52W High	-42.9%	-61.2%
% from 52W Low	37.5%	21.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.54x
FCF Yield (TTM)	0.0%	-32.4%
Earnings Yield (TTM)	-3.2%	-38.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-51.4
EV/GP/RG	N/A	0.17
Ticker research	View COAG research	View RARE research